METAVIA INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
METAVIA INC. (MTVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.13 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-03-20
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was -174.00K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-06-30 was 140.00K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-03-31 was 40.00K shares.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.13K shares, a 47.87% decline from fiscal 2022.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 6.00K shares, a 99.11% decline from fiscal 2021.
- METAVIA INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 676.67K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | 3.13K shares 10-K · filed 2025-03-20 | ||||
| 2023-06-30 | 3.13K shares 10-Q · filed 2024-08-14 | ||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -174.00K shares derived: sum of 2 quarters · filed 2023-03-30 | -34.01K shares derived: sum of 3 quarters · filed 2023-03-30 | 6.00K shares 10-K · filed 2023-03-30 | |
| 2022-09-30 | -174.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -34.01K shares derived: sum of 2 quarters · filed 2022-11-14 | 6.00K shares 10-Q · filed 2022-11-14 | 622.66K shares derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-06-30 | 140.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 180.00K shares 10-Q · filed 2022-08-12 | 796.67K shares derived: sum of 3 quarters · filed 2022-08-12 | ||
| 2022-03-31 | 40.00K shares 10-Q · filed 2022-05-13 | 656.67K shares derived: sum of 2 quarters · filed 2022-05-13 | |||
| 2021-12-31 | 616.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 676.67K shares 10-K · filed 2022-03-31 | |||
| 2021-09-30 | 60.00K shares 10-Q · filed 2021-11-15 | ||||
| 2020-09-30 | 60.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 60.00K shares derived: sum of 2 quarters · filed 2021-11-15 | 420.00K shares 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 360.00K shares 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | 360.00K shares 10-Q · filed 2021-05-17 | ||||
| 2020-01-13 | 60.00K shares 10-K · filed 2020-03-30 | ||||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-13 | 960.20K shares 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 960.20K shares 10-Q · filed 2020-08-11 | |||
| 2019-03-31 | 960.20K shares 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |